ClinicalTrials.gg
CompletedNCT03234907Updated Mar 1, 2023Results posted

Vedolizumab Intravenous (IV) Compared to Placebo in Chinese Participants With Crohn's Disease.

A Phase 3 interventional study of Vedolizumab IV and Placebo in Crohn's Disease, sponsored by Takeda. Completed at 29 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-03-01.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
215
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 39 studies testing vedolizumab in Crohn Disease — 10 open to participants now, 12 under way, 7 of them phase 3. vedolizumab · Crohn Disease.

Enrollment
13th of 39
215 · median 101
Started
2017
with 4 others
Phase 3
16 of 39
6 open now
Registered
25th of 39
by date
Lead sponsor
25 of 39
Takeda

Among the 39 studies testing vedolizumab in Crohn Disease, this one is the 13th largest by enrollment, is one of 5 that started in 2017, is one of 16 in phase 3, and was the 25th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

10 of the 39 studies testing vedolizumab in Crohn Disease are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About vedolizumab

vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing vedolizumab in Crohn Disease, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and efficacy of vedolizumab intravenous (IV) infusion as induction treatment in Chinese participants with moderately to severely active Crohn's disease (CD) at Week 10.

Read the detailed description

The drug being tested in this study is called vedolizumab. Vedolizumab will be administered as an intravenous (IV) infusion in Chinese participants. This study will investigate the efficacy and safety of vedolizumab IV as induction and maintenance therapy in participants with moderately to severely active Crohn's Disease (CD).

The study will enroll approximately 300 moderately to severely active Chinese patients with CD.

Induction Phase: participants will be randomized 2:1 to receive:

  • Vedolizumab IV 300 mg
  • Placebo IV

Participants will receive vedolizumab 300 mg or matching placebo, intravenous (IV) infusion at Weeks 0, 2, and 6 in the induction phase. At Week 10, participants will be assessed for clinical response. Results of Week 10 clinical response will determine the treatment pathway in the maintenance phase.

Maintenance Phase: participants who achieved clinical response at Week 10 will continue to receive the same treatment as they received in Induction Phase; every 8 weeks (Q8W) starting at Week 14. Participants who received vedolizumab IV or placebo in the Induction Phase and did not achieve clinical response at Week 10 will receive vedolizumab every 4 weeks (Q4W) starting at Week 14.

This multi-center trial will be conducted in China. The overall time to participate in this study is 60 weeks. Participants will make multiple visits to the clinic, and will be contacted by telephone, 6 months after last dose of study drug for a long-term follow-up safety survey.

03

Conditions studied

  • Crohn's Disease

Browse trials for

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has a diagnosis of Crohn's disease (CD) established at least 3 months prior to Screening by clinical and endoscopic evidence corroborated by a histopathology report. Cases of CD established at least 6 months prior to randomization for which a histopathology report is not available will be considered based on the weight of evidence supporting the diagnosis and excluding other potential diagnosis, and must be discussed with the sponsor on a case-by-case basis prior to randomization.
  2. Has moderately to severely active CD as determined by a Crohn's Disease Activity Index (CDAI) score of 220 to 400 within 7 days prior to the first dose of study drug and 1 of the following:

    • C-reactive protein (CRP) level >2.87 mg/L during the Screening Phase, OR
    • Ileocolonoscopy with photographic documentation of a minimum of 3 nonanastomotic ulcerations (each >0.5 cm in diameter) or 10 aphtous ulcerations (involving a minimum of 10 contiguous cm of intestine) consistent with CD, within 4 months prior to randomization, OR
    • Fecal calprotectin >250 μg/g stool during the Screening Phase in conjunction with computed tomography enterography (CTE), magnetic resonance enterography (MRE), contrast enhanced small bowel radiography, or wireless capsule endoscopy revealing CD ulcerations (aphthae not sufficient), within 4 months prior to Screening
  3. Has CD involvement of the ileum and/or colon, at a minimum.
  4. Has extensive colitis or pancolitis of >8 years duration or limited colitis of >12 years duration must have documented evidence that a surveillance colonoscopy was performed within 12 months prior to initial screening (may be performed during Screening if not performed in previous 12 months).
  5. Has a family history of colorectal cancer, personal history of increased colorectal cancer risk, age >50 years, or other known risk factor must be up-to-date on colorectal cancer surveillance (may be performed during Screening).
  6. Has demonstrated an inadequate response to, loss of response to, or intolerance of at least 1 of the following agents as defined below:

    • .
    • Immunomodulators.
    • Tumor necrosis factor-alpha (TNF-α) antagonists.

Exclusion criteria

Exclusion Criteria:

  1. Has evidence of abdominal abscess at the initial Screening Visit.
  2. Has had extensive colonic resection, subtotal or total colectomy.
  3. Has a history of >3 small bowel resections or diagnosis of short bowel syndrome.
  4. Has had ileostomy, colostomy, known fixed symptomatic stenosis of the intestine, or evidence of fixed stenosis, or small bowel stenosis with prestenotic dilation.
  5. Has had previous exposure to approved or anti-integrins (e.g., natalizumab, efalizumab, etrolizumab, or AMG-181), or MAdCAM-1 antagonists, or rituximab.
  6. Has used topical (rectal) treatment with 5-ASA, enemas/suppositories or traditional Chinese medications for CD treatment within 2 weeks of the administration of the first dose of study drug.
  7. Requires currently or is anticipated to require surgical intervention for CD during the study.
  8. Has a history or evidence of adenomatous colonic polyps that have not been removed.
  9. Has a history or evidence of colonic mucosal dysplasia including low or high-grade dysplasia, as well as indeterminate for dysplasia.
  10. Has a suspected or confirmed diagnosis of ulcerative colitis, indeterminate colitis, ischemic colitis, and radiation colitis.
  11. Has evidence of treatment for C.difficile infection or other intestinal pathogen with 28 days prior to first dose of study drug.
  12. Has chronic virus (HBV) infection or chronic virus (HCV) infection.
  13. Has active or latent tuberculosis.
  14. Has any identified congenital or acquired immunodeficiency (e.g., common variable immunodeficiency, [HIV] infection, organ transplantation).
  15. Has any history of , except for the following: (a) adequately-treated nonmetastatic basal cell skin cancer; (b) squamous cell skin cancer that has been adequately treated and that has not recurred for at least 1 year prior to randomization; and (c) history of cervical carcinoma in situ that has been adequately treated and that has not recurred for at least 3 years prior to randomization. Participants with remote history of malignancy (e.g., >10 years since completion of curative therapy without recurrence) will be considered based on the nature of the malignancy and the therapy received and must be discussed with the sponsor on a case-by-case basis prior to randomization.
  16. Has a history of any major neurological disorders, including stroke, multiple sclerosis, brain tumor, or neurodegenerative disease.
  17. Has a positive progressive multifocal leukoencephalopathy (PML) subjective symptom checklist at Screening or prior to the administration of the first dose of study drug at Week 0.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
215 participants (actual)

Study arms

  • Placebo comparator
    Induction Phase: Placebo

    Placebo, IV, infusion, once at Weeks 0, 2, and 6 in the Induction Phase.

    Drug: Vedolizumab IV

  • Experimental
    Induction Phase: Vedolizumab 300 mg

    Vedolizumab 300 milligram (mg), IV infusion, once at Weeks 0, 2, and 6 in the Induction Phase.

    Drug: Placebo

  • Placebo comparator
    Maintenance Phase: Induction Placebo to Placebo Q4W

    Participants who received placebo in the Induction Phase and achieved clinical response at Week 10 continued to receive placebo in the Maintenance Phase. Vedolizumab placebo-matching, IV infusion, once every 4 weeks (Q4W), from Week 14 to Week 58.

    Drug: Vedolizumab IV · Drug: Placebo

  • Experimental
    Maintenance Phase: Induction Placebo to Vedolizumab 300 mg Q4W

    Participants who received placebo in the Induction Phase and did not achieve clinical response at Week 10 received vedolizumab in the Maintenance Phase. Vedolizumab 300 mg, IV infusion, Q4W, from Week 14 to Week 58.

    Drug: Vedolizumab IV

  • Experimental
    Maintenance Phase: Induction Vedolizumab 300 mg to Vedolizumab 300 mg Q8W

    Participants who received vedolizumab in the Induction Phase and achieved clinical response at Week 10 continued to receive vedolizumab in the Maintenance Phase. Vedolizumab 300 mg, IV infusion, once every 8 weeks (Q8W), at Weeks 14, 22, 30, 38, 46 and 54 and vedolizumab placebo-matching, IV infusion, Q8W, at Weeks 18, 26, 34, 42, 50 and 58 to maintain double-blind.

    Drug: Placebo

  • Experimental
    Maintenance Phase: Induction Vedolizumab 300 mg to Vedolizumab 300 mg Q4W

    Participants who received vedolizumab in the Induction Phase and did not achieve clinical response at Week 10 received vedolizumab in the Maintenance Phase. Vedolizumab 300 mg, IV infusion, Q4W, from Week 14 to Week 58.

    Drug: Vedolizumab IV

Interventions

  • Vedolizumab IV infusion

  • DrugPlacebo

    Vedolizumab placebo-matching

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Enhanced Clinical Response in the Induction Phase at Week 10

    Enhanced clinical response was defined as ≥100-point decrease from Baseline in the Crohn's Disease Activity Index (CDAI) score at Week 10. A CDAI is a multi-item instrument which measures severity of active Crohn's Disease monitored over 7 days includes participant reported symptoms, physician-assessed signs, and laboratory markers. CDAI score is equal to sum of weighted scores for subjective items (number of liquid/soft stools, degree of abdominal pain, general well-being); and objective items (use of anti-diarrhoeal medication, abdominal mass, haematocrit, presence of extraintestinal manifestation, body weight). CDAI scores range approximately from 0 to 600, higher scores indicating greater disease activity.

    Time frame: Week 10

Secondary outcomes

  1. Percentage of Participants With Clinical Remission in the Induction Phase at Week 10

    Clinical remission was defined as CDAI score of ≤150 points at Week 10. A CDAI is a multi-item instrument which measures severity of active Crohn's Disease monitored over 7 days includes participant reported symptoms, physician-assessed signs, and laboratory markers. CDAI score is equal to sum of weighted scores for subjective items (number of liquid/soft stools, degree of abdominal pain, general well-being); and objective items (use of anti-diarrhoeal medication, abdominal mass, haematocrit, presence of extraintestinal manifestation, body weight). CDAI scores range approximately from 0 to 600, higher scores indicating greater disease activity

    Time frame: Week 10

07

Results

Posted Sep 21, 2022

Participant flow

Participants took part in the study at 27 investigative sites in China from 3 August 2017 to 14 August 2020.

Induction Phase (Week 0 to Week 10)
Participant flow — Induction Phase (Week 0 to Week 10)
MilestoneInduction Phase: PlaceboInduction Phase: Vedolizumab 300 mgMaintenance Phase: Induction Placebo to Placebo Q4WMaintenance Phase: Induction Placebo to Vedolizumab 300 mg Q4WMaintenance Phase: Induction Vedolizumab 300 mg to Vedolizumab 300 mg Q8WMaintenance Phase: Induction Vedolizumab 300 mg to Vedolizumab 300 mg Q4W
Started711440000
Treated701440000
Completed611380000
Not completed1060000
Withdrew: Protocol deviation110000
Withdrew: Withdrawal by subject640000
Withdrew: Lack of efficacy200000
Withdrew: Enrolled but not treated110000
Maintenance Phase (Week 10 to Week 60)
Participant flow — Maintenance Phase (Week 10 to Week 60)
MilestoneInduction Phase: PlaceboInduction Phase: Vedolizumab 300 mgMaintenance Phase: Induction Placebo to Placebo Q4WMaintenance Phase: Induction Placebo to Vedolizumab 300 mg Q4WMaintenance Phase: Induction Vedolizumab 300 mg to Vedolizumab 300 mg Q8WMaintenance Phase: Induction Vedolizumab 300 mg to Vedolizumab 300 mg Q4W
Started0018384688
Completed0017273667
Not completed001111021
Withdrew: Withdrawal by subject000437
Withdrew: Lack of efficacy001334
Withdrew: Reason not specified0004410

Outcome measures

PrimaryPercentage of Participants With Enhanced Clinical Response in the Induction Phase at Week 10

Enhanced clinical response was defined as ≥100-point decrease from Baseline in the Crohn's Disease Activity Index (CDAI) score at Week 10. A CDAI is a multi-item instrument which measures severity of active Crohn's Disease monitored over 7 days includes participant reported symptoms, physician-assessed signs, and laboratory markers. CDAI score is equal to sum of weighted scores for subjective items (number of liquid/soft stools, degree of abdominal pain, general well-being); and objective items (use of anti-diarrhoeal medication, abdominal mass, haematocrit, presence of extraintestinal manifestation, body weight). CDAI scores range approximately from 0 to 600, higher scores indicating greater disease activity.

Time frame:
Week 10
Reported as:
Number · percentage of participants
Percentage of Participants With Enhanced Clinical Response in the Induction Phase at Week 10
percentage of participantsInduction Phase: PlaceboInduction Phase: Vedolizumab 300 mg
Percentage of Participants With Enhanced Clinical Response in the Induction Phase at Week 1024.3 (14.8 to 36.0)19.4 (13.3 to 26.9)
Statistical analysis
  • Induction Phase: Placebo vs Induction Phase: Vedolizumab 300 mg · Cui-Hung-Wang (CHW) test · p = =0.347 (P-value was based on CHW test, based on weighted CMH chi-square test, with stratification according to: (1)previous failure of TNF-α antagonist therapy/concomitant use of immunomodulators(Yes/No);(2)concomitant use of oral corticosteroids(Yes/No).) · Risk difference (rd): -5.2 · 95% CI -17.2 to 6.8Mantel-Haenszel estimate of the treatment difference and its variance was used to calculate the 95% confidence interval for the treatment difference. Adjustment to the stratification factors was implemented.
SecondaryPercentage of Participants With Clinical Remission in the Induction Phase at Week 10

Clinical remission was defined as CDAI score of ≤150 points at Week 10. A CDAI is a multi-item instrument which measures severity of active Crohn's Disease monitored over 7 days includes participant reported symptoms, physician-assessed signs, and laboratory markers. CDAI score is equal to sum of weighted scores for subjective items (number of liquid/soft stools, degree of abdominal pain, general well-being); and objective items (use of anti-diarrhoeal medication, abdominal mass, haematocrit, presence of extraintestinal manifestation, body weight). CDAI scores range approximately from 0 to 600, higher scores indicating greater disease activity

Time frame:
Week 10
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Remission in the Induction Phase at Week 10
percentage of participantsInduction Phase: PlaceboInduction Phase: Vedolizumab 300 mg
Percentage of Participants With Clinical Remission in the Induction Phase at Week 1011.4 (5.1 to 21.3)9.0 (4.9 to 14.9)
Statistical analysis
  • Induction Phase: Placebo vs Induction Phase: Vedolizumab 300 mg · Cochran-Mantel-Haenszel · p = =0.531 (P-value based on Cochran-Mantel-Haenszel, weighted CMH chi-square test, with stratification according to:(1)previous failure of TNF-α antagonist therapy/concomitant use of immunomodulators(Yes/No);(2)concomitant use of oral corticosteroids(Yes/No).) · Risk difference (rd): -2.7 · 95% CI -11.5 to 6.0Mantel-Haenszel estimate of the treatment difference and its variance was used to calculate the 95% confidence interval for the treatment difference. Adjustment to the stratification factors was implemented.

Adverse events

Collected over From first dose of the study drug up to 18 weeks after the last dose (Induction Phase: Up to Week 28; Maintenance Phase: Up to Week 78). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Induction Phase: Placebo0/70 (0%)5/70 (7.1%)26/70 (37.1%)
Induction Phase: Vedolizumab 300 mg0/144 (0%)12/144 (8.3%)60/144 (41.7%)
Maintenance Phase: Induction Placebo to Placebo Q4W0/18 (0%)3/18 (16.7%)12/18 (66.7%)
Maintenance Phase: Induction Placebo to Vedolizumab 300 mg Q4W0/38 (0%)10/38 (26.3%)23/38 (60.5%)
Maintenance Phase: Induction Vedolizumab 300 mg to Vedolizumab 300 mg Q8W0/46 (0%)14/46 (30.4%)27/46 (58.7%)
Maintenance Phase: Induction Vedolizumab 300 mg to Vedolizumab 300 mg Q4W1/88 (1.1%)25/88 (28.4%)63/88 (71.6%)
Most frequent serious events
Showing 10 of 31
Most frequent serious events
EventInduction Phase: PlaceboInduction Phase: Vedolizumab 300 mgMaintenance Phase: Induction Placebo to Placebo Q4WMaintenance Phase: Induction Placebo to Vedolizumab 300 mg Q4WMaintenance Phase: Induction Vedolizumab 300 mg to Vedolizumab 300 mg Q8WMaintenance Phase: Induction Vedolizumab 300 mg to Vedolizumab 300 mg Q4W
Crohn's diseaseGastrointestinal disorders0/704/1441/185/389/467/88
Small intestinal obstructionGastrointestinal disorders0/700/1441/180/380/461/88
Anal abscessInfections and infestations1/701/1441/180/381/462/88
Gastrointestinal haemorrhageGastrointestinal disorders0/700/1440/180/382/460/88
Intestinal obstructionGastrointestinal disorders0/700/1440/180/380/463/88
Abdominal painGastrointestinal disorders1/700/1440/181/380/460/88
Anal fistulaGastrointestinal disorders0/701/1440/181/380/461/88
Gastrointestinal fistulaGastrointestinal disorders1/700/1440/181/380/461/88
HaematocheziaGastrointestinal disorders0/702/1440/181/380/461/88
AnaemiaBlood and lymphatic system disorders0/700/1440/181/380/462/88
Most frequent other events
Showing 10 of 23
Most frequent other events
EventInduction Phase: PlaceboInduction Phase: Vedolizumab 300 mgMaintenance Phase: Induction Placebo to Placebo Q4WMaintenance Phase: Induction Placebo to Vedolizumab 300 mg Q4WMaintenance Phase: Induction Vedolizumab 300 mg to Vedolizumab 300 mg Q8WMaintenance Phase: Induction Vedolizumab 300 mg to Vedolizumab 300 mg Q4W
PyrexiaGeneral disorders2/7013/1443/182/386/4611/88
ArthralgiaMusculoskeletal and connective tissue disorders0/700/1443/182/381/467/88
Upper respiratory tract infectionInfections and infestations3/7011/1440/184/385/4612/88
Blood urine presentInvestigations0/700/1440/185/381/468/88
AnaemiaBlood and lymphatic system disorders6/708/1442/182/386/4610/88
Mouth ulcerationGastrointestinal disorders3/7010/1441/181/382/4610/88
Protein urine presentInvestigations5/7013/1441/183/384/4610/88
NasopharyngitisInfections and infestations6/7014/1441/182/382/4610/88
Abdominal painGastrointestinal disorders0/700/1442/180/381/466/88
Lymphocyte count decreasedInvestigations7/708/1442/183/384/463/88

Baseline characteristics

FAS for the induction phase study included all randomized participants who received any amount of blinded study drug during the Induction Phase.

Age, Continuous
Age, Continuous(years)Induction Phase: PlaceboInduction Phase: Vedolizumab 300 mgTotal
Mean31.1 ± 8.1231.1 ± 10.1031.1 ± 9.48
Sex: Female, Male
Sex: Female, Male(Participants)Induction Phase: PlaceboInduction Phase: Vedolizumab 300 mgTotal
Female164864
Male5496150
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Induction Phase: PlaceboInduction Phase: Vedolizumab 300 mgTotal
Hispanic or Latino000
Not Hispanic or Latino70144214
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Induction Phase: PlaceboInduction Phase: Vedolizumab 300 mgTotal
American Indian or Alaska Native000
Asian70144214
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Weight
Weight(kg)Induction Phase: PlaceboInduction Phase: Vedolizumab 300 mgTotal
Mean54.61 ± 10.66254.33 ± 10.38854.42 ± 10.454
Height
Height(cm)Induction Phase: PlaceboInduction Phase: Vedolizumab 300 mgTotal
Mean168.18 ± 7.785166.96 ± 8.064167.36 ± 7.976
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Induction Phase: PlaceboInduction Phase: Vedolizumab 300 mgTotal
Mean19.21 ± 2.97819.38 ± 2.74219.33 ± 2.815
08

Study locations

29 sites
  • Gastroenterology
    Hefei, Anhui 230024, China
  • Gastroenterology
    Beijing, Beijing 100050, China
  • Gastroenterology
    Beijing, Beijing 100730, China
  • Gastroenterology
    Chongqing, Chongqing 400037, China
  • Gastroenterology
    Fuzhou, Fujian 350025, China
  • Gastroenterology
    Xiamen, Fujian 361004, China
  • Gastroenterology
    Guangzhou, Guangdong 510080, China
  • Gastroenterology
    Guangzhou, Guangdong 510515, China
  • Gastroenterology
    Guangzhou, Guangdong 510655, China
  • Gastroenterology
    Wuhan, Hubei 430000, China
  • Gastroenterology
    Wuhan, Hubei 430030, China
  • Gastroenterology
    Wuhan, Hubei 430060, China
  • Gastroenterology
    Changsha, Hunan 410008, China
  • Gastroenterology
    Changsha, Hunan 410011, China
  • Gastroenterology
    Changsha, Hunan 410013, China
  • Gastroenterology
    Nanjing, Jiangsu 210008, China
  • Gastroenterology
    Nanjing, Jiangsu 210029, China
  • Gastroenterology
    Wuxi, Jiangsu 241023, China
  • Gastroenterology
    Nanchang, Jiangxi 330006, China
  • Gastroenterology
    Changchun, Jilin 130000, China
  • Gastroenterology
    Shenyang, Liaoning 110022, China
  • Gastroenterology
    Shanghai, Shanghai 200025, China
  • Gastroenterology
    Shanghai, Shanghai 200032, China
  • Gastroenterology
    Shanghai, Shanghai 200072, China
  • Gastroenterology
    Shanghai, Shanghai 200092, China
  • Gastroenterology
    Chengdu, Sichuan 610041, China
  • Gastroenterology
    Kunming, Yunnan 650032, China
  • Gastroenterology
    Hangzhou, Zhejiang 310009, China
  • Gastroenterology
    Hangzhou, Zhejiang 310016, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Aug 2020, 36 months.

Results were first posted in Sep 2022, 2 years 1 month after primary completion. A results delay was requested in Jul 2021.

Of 70 industry-sponsored phase 3 interventional studies under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 69. This study's 36 months is below that.

Counting every sponsor, half of 88 studies reached it within 49 months; a quarter within 36 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2017
First posted
Jul 31, 2017
StartActual
Aug 3, 2017
Primary completionActual
Aug 14, 2020
CompletionActual
Aug 14, 2020
Results delay requested
Jul 27, 2021
Results first posted
Sep 21, 2022
Last update
Mar 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03234907
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jul 31, 2017
Start date
Aug 3, 2017
Primary completion
Aug 14, 2020
Completion
Aug 14, 2020
Results posted
Sep 21, 2022
Last update
Mar 1, 2023

Study contacts

Study Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vedolizumab

Start the discussion